fianlimab and cemiplimab in patients with advanced melanoma
Published 1 year ago • 413 plays • Length 8:43Download video MP4
Download video MP3
Similar videos
-
3:22
clinical activity of fianlimab, an anti-lag-3 mab combined with cemiplimab in advanced melanoma
-
3:26
post adjuvant pd-1 analysis of fianlimab and cemiplimab in melanoma
-
3:35
keynote-006: the efficacy of ipilimumab after pembrolizumab in patients with advanced melanoma
-
2:54
combining nivolumab and ipilimumab in patients with resected stage iv melanoma
-
2:43
clinical & tumor characteristics of patients with recurrent melanoma upon immunotherapy
-
10:42
what is new in melanoma?
-
1:43
future directions in melanoma
-
0:53
polaris: encorafenib/binimetinib for advanced brafv600 melanoma
-
0:33
keynote-716: pembrolizumab in stage 2b/2c cutaneous melanoma
-
1:12
current trials in the treatment of melanoma
-
2:22
adjuvant nivolumab in patents with high-risk resected melanoma
-
27:01
immunotherapy for advanced melanoma
-
6:17
relativity-047: relatlimab, an anti-lag-3 antibody nivolumab in first-line advanced melanoma
-
0:46
the benefits of nivolumab and relatlimab in melanoma
-
1:59
checkmate 238: nivolumab versus ipilimumab in stage iii melanoma
-
1:13
clinical trials investigating the treatment of melanoma
-
2:10
pembrolizumab, tumor response, and survival in advanced melanoma
-
5:37
phase iii trial shows pembrolizumab preferable to ipilimumab in advanced melanoma